Police to call Papagomo over alleged assault on Syed Saddiq [ 1m ago ]

Samsung Bioepis And C-Bridge Capital To Develop And Commercialize Next-Generation Biosimilars In China

Last update: 11/02/2019
  • Agreement covers Samsung Bioepis’ third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS® [1](ranibizumab) and SOLIRIS® [2] (eculizumab), respectively

  • Partnership brings together Samsung Bioepis’ proven agile biologics development platform and C-Bridge’s strong capital resource and China healthcare expertise

  • C-Bridge Capital forms new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.

INCHEON, Korea, Feb 11 (Bernama) -- Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS® (ranibizumab) and SOLIRIS® (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing HERCEPTIN®[3] (trastuzumab).

Under the agreement, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration and commercialization in China. Samsung Bioepis will receive an upfront payment, as well as royalties on sales. Additional financial details were not disclosed.



For the full text, click here

       Previous Top Story